Last reviewed · How we verify
NCT06722911
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Phase 2 trial testing Nimotuzumab in Pancreatic Cancer Resectable in 57 participants. Currently enrolling.
30 September 2028
Quick facts
| Lead sponsor | Zhejiang Provincial People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 57 |
| Start date | 15 November 2024 |
| Primary completion | 30 September 2028 |
| Estimated completion | 30 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Nimotuzumab — full drug profile →
- AG
Conditions studied
- Pancreatic Cancer Resectable — all drugs for Pancreatic Cancer Resectable →
Sponsor
Zhejiang Provincial People's Hospital
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer Resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06722911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nimotuzumab
Trials testing the same drug.
- NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
- NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting
Other recruiting trials for Pancreatic Cancer Resectable
Currently open trials in the same condition.
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
- NCT06914349 — Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure · NA · recruiting
- NCT07157605 — Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) · recruiting
- NCT06496373 — Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer · EARLY_PHASE1 · recruiting
Other Zhejiang Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
- NCT07312422 — LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study · Phase 1, PHASE2 · recruiting
- NCT06975644 — Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) · NA · not yet recruiting
- NCT07068542 — Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06722911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial People's Hospital
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06722911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing